Product Description
Mechanisms of Action: AChR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fremantle Hospital and Health Service
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease|Stroke
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12609000975291 |
ACTRN12609000975291 | P2 |
Completed |
Stroke |
2013-03-22 |
2024-08-29 |
Treatments |
|
NCT00001933 |
99-N-0139 | P2 |
Completed |
Alzheimer Disease |
None |
2019-03-21 |
Treatments |